6 O
ADVERSE O
REACTIONS O
Six O
serious O
adverse O
reactions O
were O
reported O
by O
four O
patients O
during O
the O
clinical O
program O
. O

These O
serious O
adverse O
reactions O
were O
Mycobacterium B-OSE_Labeled_AE
intracellulare I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
; O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
and O
colitis B-OSE_Labeled_AE
; O
sinusitis B-OSE_Labeled_AE
and O
bronchitis B-OSE_Labeled_AE
; O
and O
Streptococcus B-OSE_Labeled_AE
pneumoniae I-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

The O
most O
commonly O
reported O
adverse O
reaction O
associated O
with O
ARCALYST O
was O
injection B-OSE_Labeled_AE
- I-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
ISR O
) O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

The O
next O
most O
commonly O
reported O
adverse O
reaction O
was O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.3 O
) O
] O
. O

Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
herein O
reflect O
exposure O
to O
ARCALYST O
in O
600 O
patients O
, O
including O
85 O
exposed O
for O
at O
least O
6 O
months O
and O
65 O
exposed O
for O
at O
least O
one O
year O
. O

These O
included O
patients O
with O
CAPS B-Not_AE_Candidate
, O
patients O
with O
other O
diseases O
, O
and O
healthy O
volunteers O
. O

Approximately O
60 O
patients O
with O
CAPS B-Not_AE_Candidate
have O
been O
treated O
weekly O
with O
160 O
mg O
of O
ARCALYST O
. O

The O
pivotal O
trial O
population O
included O
47 O
patients O
with O
CAPS B-Not_AE_Candidate
. O

These O
patients O
were O
between O
the O
ages O
of O
22 O
and O
78 O
years O
( O
average O
51 O
years O
) O
. O

Thirty-one O
patients O
were O
female O
and O
16 O
were O
male O
. O

All O
of O
the O
patients O
were O
White/Caucasian O
. O

Six O
pediatric O
patients O
( O
12-17 O
years O
) O
were O
enrolled O
directly O
into O
the O
open-label O
extension O
phase O
. O

EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
reported O
by O
patients O
with O
CAPS O
treated O
with O
ARCALYST O
are O
injection-site O
reactions O
and O
upper O
respiratory O
tract O
infections O
. O

( O
6.2 O
, O
6.3 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Regeneron O
at O
1-877-REGN-777 O
( O
1-877-734-6777 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Part O
A O
of O
the O
clinical O
trial O
was O
conducted O
in O
patients O
with O
CAPS B-Not_AE_Candidate
who O
were O
naive O
to O
treatment O
with O
ARCALYST O
. O

Part O
A O
of O
the O
study O
was O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
six-week O
study O
comparing O
ARCALYST O
to O
placebo O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Table O
1 O
reflects O
the O
frequency O
of O
adverse O
events O
reported O
by O
at O
least O
two O
patients O
during O
Part O
A O
. O

Table O
1 O
: O
Most O
Frequent O
Adverse O
Reactions O
( O
Part O
A O
, O
Reported O
by O
at O
Least O
Two O
Patients O
) O
Adverse O
Event O
ARCALYST160 O
mg O
( O
n O
= O
23 O
) O
Placebo O
( O
n= O
24 O
) O
Any O
AE O
17 O
( O
74 O
% O
) O
13 O
( O
54 O
% O
) O
Injection B-OSE_Labeled_AE
- I-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
11 O
( O
48 O
% O
) O
3 O
( O
13 O
% O
) O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
6 O
( O
26 O
% O
) O
1 O
( O
4 O
% O
) O
Nausea B-NonOSE_AE
1 O
( O
4 O
% O
) O
3 O
( O
13 O
% O
) O
Diarrhea B-NonOSE_AE
1 O
( O
4 O
% O
) O
3 O
( O
13 O
% O
) O
Sinusitis B-OSE_Labeled_AE
2 O
( O
9 O
% O
) O
1 O
( O
4 O
% O
) O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
upper I-NonOSE_AE
0 O
2 O
( O
8 O
% O
) O
Cough B-OSE_Labeled_AE
2 O
( O
9 O
% O
) O
0 O
Hypoesthesia B-OSE_Labeled_AE
2 O
( O
9 O
% O
) O
0 O
Stomach B-NonOSE_AE
discomfort I-NonOSE_AE
1 O
( O
4 O
% O
) O
1 O
( O
4 O
% O
) O
Urinary B-NonOSE_AE
tract I-NonOSE_AE
infection I-NonOSE_AE
1 O
( O
4 O
% O
) O
1 O
( O
4 O
% O
) O
6.2 O
Injection-Site O
Reactions O
In O
patients O
with O
CAPS B-Not_AE_Candidate
, O
the O
most O
common O
and O
consistently O
reported O
adverse O
event O
associated O
with O
ARCALYST O
was O
injection B-OSE_Labeled_AE
- I-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
ISR O
) O
. O

The O
ISRs B-OSE_Labeled_AE
included O
erythema O
, O
swelling O
, O
pruritis O
, O
mass O
, O
bruising O
, O
inflammation O
, O
pain O
, O
edema O
, O
dermatitis O
, O
discomfort O
, O
urticaria O
, O
vesicles O
, O
warmth O
and O
hemorrhage O
. O

Most O
injection B-OSE_Labeled_AE
- I-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
lasted O
for O
one O
to O
two O
days O
. O

No O
ISRs B-NonOSE_AE
were O
assessed O
as O
severe O
, O
and O
no O
patient O
discontinued O
study O
participation O
due O
to O
an O
ISR B-NonOSE_AE
. O

6.3 O
Infections O
During O
Part O
A O
, O
the O
incidence O
of O
patients O
reporting O
infections B-OSE_Labeled_AE
was O
greater O
with O
ARCALYST O
( O
48 O
% O
) O
than O
with O
placebo O
( O
17 O
% O
) O
. O

In O
Part O
B O
, O
randomized O
withdrawal O
, O
the O
incidence O
of O
infections B-NonOSE_AE
were O
similar O
in O
the O
ARCALYST O
( O
18 O
% O
) O
and O
the O
placebo O
patients O
( O
22 O
% O
) O
. O

Part O
A O
of O
the O
trial O
was O
initiated O
in O
the O
winter O
months O
, O
while O
Part O
B O
was O
predominantly O
performed O
in O
the O
summer O
months O
. O

In O
placebo-controlled O
studies O
across O
a O
variety O
of O
patient O
populations O
encompassing O
360 O
patients O
treated O
with O
rilonacept O
and O
179 O
treated O
with O
placebo O
, O
the O
incidence O
of O
infections B-OSE_Labeled_AE
was O
34 O
% O
and O
27 O
% O
( O
2.15 O
per O
patient-exposure O
year O
and O
1.81 O
per O
patient-exposure O
year O
) O
, O
respectively O
, O
for O
rilonacept O
and O
placebo O
. O

Serious O
Infections B-NonOSE_AE
: O
One O
patient O
receiving O
ARCALYST O
for O
an O
unapproved O
indication O
in O
another O
study O
developed O
an O
infection B-NonOSE_AE
in I-NonOSE_AE
his I-NonOSE_AE
olecranon I-NonOSE_AE
bursa I-NonOSE_AE
with I-NonOSE_AE
Mycobacterium I-NonOSE_AE
intracellulare I-NonOSE_AE
. O

The O
patient O
was O
on O
chronic O
glucocorticoid O
treatment O
. O

The O
infection B-NonOSE_AE
occurred O
after O
an O
intraarticular O
glucocorticoid O
injection O
into O
the O
bursa O
with O
subsequent O
local O
exposure O
to O
a O
suspected O
source O
of O
mycobacteria O
. O

The O
patient O
recovered O
after O
the O
administration O
of O
the O
appropriate O
antimicrobial O
therapy O
. O

One O
patient O
treated O
for O
another O
unapproved O
indication O
developed O
bronchitis B-NonOSE_AE
/ O
sinusitis B-NonOSE_AE
, O
which O
resulted O
in O
hospitalization O
. O

One O
patient O
died B-NonOSE_AE
in O
an O
open-label O
study O
of O
CAPS B-Not_AE_Candidate
from O
Streptococcus B-NonOSE_AE
pneumoniae I-NonOSE_AE
meningitis I-NonOSE_AE
. O

6.4 O
Malignancies O
[ O
s O
ee O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

6.5 O
Hematologic O
Events O
One O
patient O
in O
a O
study O
in O
an O
unapproved O
indication O
developed O
transient O
neutropenia B-NonOSE_AE
( O
ANC B-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
x I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
9 I-NonOSE_AE
/ I-NonOSE_AE
L I-NonOSE_AE
) O
after O
receiving O
a O
large O
dose O
( O
2000 O
mg O
intravenously O
) O
of O
ARCALYST O
. O

The O
patient O
did O
not O
experience O
any O
infection B-NonOSE_AE
associated I-NonOSE_AE
with I-NonOSE_AE
the I-NonOSE_AE
neutropenia I-NonOSE_AE
. O

6.6 O
Immunogenicity O
Antibodies B-OSE_Labeled_AE
directed O
against I-OSE_Labeled_AE
the O
receptor O
domains O
of O
rilonacept I-OSE_Labeled_AE
were O
detected I-OSE_Labeled_AE
by O
an O
ELISA O
assay O
in O
patients O
with O
CAPS B-Not_AE_Candidate
after O
treatment O
with O
ARCALYST O
. O

Nineteen O
of O
55 O
patients O
( O
35 O
% O
) O
who O
had O
received O
ARCALYST O
for O
at O
least O
6 O
weeks O
tested O
positive O
for O
treatment B-OSE_Labeled_AE
- I-OSE_Labeled_AE
emergent I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
on O
at O
least O
one O
occasion O
. O

Of O
the O
19 O
, O
seven O
tested O
positive O
at O
the O
last O
assessment O
( O
Week O
18 O
or O
24 O
of O
the O
open-label O
extension O
period O
) O
, O
and O
five O
patients O
tested O
positive B-OSE_Labeled_AE
for O
neutralizing I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
on O
at O
least O
one O
occasion O
. O

There O
was O
no O
correlation O
of O
antibody O
activity O
and O
either O
clinical O
effectiveness O
or O
safety O
. O

The O
data O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to O
the O
rilonacept O
receptor O
domains O
in O
specific O
assays O
, O
and O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assays O
. O

The O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
antibody O
) O
positivity I-NonOSE_AE
in O
an O
assay O
is O
highly O
dependent O
on O
several O
factors O
including O
assay O
sensitivity O
and O
specificity O
, O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies O
to O
rilonacept O
with O
the O
incidence O
of O
antibodies O
to O
other O
products O
may O
be O
misleading O
. O

6.7 O
Lipid O
profiles O
Cholesterol B-Not_AE_Candidate
and O
lipid O
levels O
may I-Not_AE_Candidate
be I-Not_AE_Candidate
reduced I-Not_AE_Candidate
in O
patients O
with O
chronic B-Not_AE_Candidate
inflammation I-Not_AE_Candidate
. O

Patients O
with O
CAPS B-Not_AE_Candidate
treated O
with O
ARCALYST O
experienced O
increases B-OSE_Labeled_AE
in O
their O
mean O
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
, O
HDL O
cholesterol O
, O
LDL O
cholesterol O
, O
and O
triglycerides O
. O

The O
mean O
increases B-OSE_Labeled_AE
from O
baseline O
for O
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
, O
HDL O
cholesterol O
, O
LDL O
cholesterol O
, O
and O
triglycerides O
were O
19 O
mg/dL O
, O
2 O
mg/dL O
, O
10 O
mg/dL O
, O
and O
57 O
mg/dL O
respectively O
after O
6 O
weeks O
of O
open-label O
therapy O
. O

Physicians O
should O
monitor O
the O
lipid O
profiles O
of O
their O
patients O
( O
for O
example O
after O
2-3 O
months O
) O
and O
consider O
lipid-lowering O
therapies O
as O
needed O
based O
upon O
cardiovascular O
risk O
factors O
and O
current O
guidelines O
. O

